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SYNOPSIS 
The prevalence of non-B non-C hepatocellular carcinoma (NBNC HCC) has increased. 
We categorized its etiology according to alcohol intake and presence of steatosis. 
Absence of steatosis in hepatic parenchyma had a significant impact on disease-free 
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ABSTRACT 
Background. Although the prevalence of non-B non-C hepatocellular carcinoma 
(NBNC HCC) has increased, its clinicopathologic characteristics remain unclear. 
Methods. We retrospectively analyzed 518 HCC patients who underwent hepatic 
resection. Hepatitis B surface antigen- and hepatitis C antibody-negative patients were 
categorized into the NBNC HCC group (n=145); others were categorized into the 
hepatitis B or C HCC (BC HCC) group (n=373). We subdivided the etiologies of NBNC 
HCC according to alcohol intake and presence of steatosis. 
Results. NBNC HCC was associated with nonalcoholic fatty liver disease (NAFLD) 
(13.1%), fatty liver disease (FLD) with moderate alcohol intake (9.0%), alcoholic liver 
disease (ALD) (29.7%), cryptogenic disease (44.1%), and other known etiologies 
(4.1%). The prevalence of obesity, diabetes mellitus, and hypertension was higher and 
hepatic function was better in the NBNC HCC group, which had significantly larger 
tumors than the BC HCC group. The entire NBNC HCC group displayed similar overall 
and disease-free survival as the BC HCC group. Among the subdivisions, NAFLD-
associated HCC patients had significantly better disease-free survival than ALD-
associated HCC and BC HCC patients. Microvascular invasion (hazard ratio [HR], 
2.30; 95% confidence interval [CI], 1.33–3.96) and steatosis area ˂5% of non-cancerous 
region (HR, 2.13; 95% CI, 1.21–3.93) were associated with disease-free survival in 
NBNC HCC patients.  
Conclusions. The prognosis of NBNC HCC was similar to that of BC HCC. Among 
NBNC HCC patients, NAFLD-associated HCC patients had a relatively low recurrence 
risk. Absence of steatosis in hepatic parenchyma had a significant impact on disease-
free survival in NBNC HCC patients. 
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Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third 
most frequent cause of cancer-related death worldwide.1,2 Liver cirrhosis is the primary 
risk factor for HCC development,3,4 which is the long-term result of chronic hepatitis B 
(HBV) or hepatitis C virus (HCV) infection or chronic alcohol consumption.5-7 Recently, 
the prevalence of hepatitis B surface antigen (HBsAg)- and hepatitis C antibody 
(HCVAb)-negative HCC—also termed non-B non-C HCC (NBNC HCC)—has rapidly 
increased8-10, whereas that of HBV- or HCV-related HCC has decreased owing to 
antiviral therapy.11  
The etiology of NBNC HCC is multifactorial and remains unorganized. In 
addition to chronic alcohol consumption, nonalcoholic fatty liver disease (NAFLD) and 
metabolic syndrome-related factors (i.e., obesity, insulin resistance, diabetes mellitus, 
dyslipidemia, and hypertension) are considered risk factors for NBNC HCC.10-16 
According to the nationwide survey of non-B non-C liver cirrhosis in Japan at the 15th 
General Meeting of the Japan Society of Hepatology, nonalcoholic steatohepatitis 
(NASH, 14.5%), alcoholic liver disease (ALD, 55.1%), fatty liver disease (FLD) with 
moderate alcohol consumption (intake, 20–70 g ethanol/day, 2.5%), primary biliary 
cirrhosis (8.0%), other biliary cirrhosis (0.8%), autoimmune hepatitis (6.8%), metabolic 
disease (0.6%), congestive disease (0.8%), parasitic disease (0.2%), other known 
etiology (0.2%), and unknown etiology (10.5%) were identified as the causes of non-B 
non-C liver cirrhosis.17 Chronic alcohol consumption, obesity-associated metabolic 
syndrome, and their common pathological consequences characterized by steatosis are 
considered essential etiological factors for categorizing NBNC HCC. Studies have 
examined the clinicopathologic characteristics of NBNC HCC; however, none 
systematically categorized NBNC HCC patients based on etiology and pathology of 
hepatic parenchyma. 
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These etiological factors may be closely associated with tumor characteristics, 
preoperative hepatic functional reserve, and the resulting surgical outcomes of NBNC 
HCC patients. We investigated the clinicopathologic features and prognostic factors of 
NBNC HCC patients who underwent hepatic resection. We categorized their etiology 
based on alcohol consumption, metabolic syndrome prevalence, and pathology of 
underlying parenchymal change, especially focusing on presence of steatosis, which is a 
key etiological criterion of NBNC HCC. 
 
PATIENTS AND METHODS 
Patients 
Between January 2000 and December 2011, 688 HCC patients underwent initial 
hepatic resection at our institution. We excluded 170 patients because the pathological 
findings of fibrosis and steatosis in the parenchyma were not precisely evaluated. The 
remaining 518 patients were divided into 2 groups: patients negative for HBsAg and 
HCVAb were categorized into the NBNC HCC group (n=145); others were included in 
the HBV- or HCV-related HCC (BC HCC) group (n=373). NBNC HCC patients were 
further categorized according to the etiological criteria of the nationwide survey of non-
B non-C liver cirrhosis in Japan at the 15th General Meeting of the Japan Society of 
Hepatology17 as: (i) ALD, with heavy alcohol consumption (ethanol intake ˃70 g/day); 
(ii) NAFLD, characterized by histological fatty liver without chronic alcohol 
consumption (ethanol intake ≤20 g/day); (iii) FLD, also characterized by histological 
fatty liver and moderate alcohol consumption (ethanol intake, 20–70 g/day); (iv) other 
known etiology (e.g., autoimmune hepatitis, cholestatic diseases, or other chronic liver 
diseases); and (v) cryptogenic diseases. Among the conventional cryptogenic HCC 
cases, we tentatively established the following criteria of non-steatotic and metabolic 
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syndrome-associated HCC (Non-Steatotic Met HCC): daily ethanol intake ˂70 g/day; 
absence of the pathological steatosis; and prevalence of one or more of metabolic 
syndrome-associated risk factors. The definitions of the risk criteria for metabolic 
syndrome were based on the international criteria16,18 with slight modification to suit the 
Japanese criteria as follows: obesity (body mass index >25 kg/m2); diabetes mellitus 
(fasting glucose ≥126 mg/dL or HbA1c ≥6.5%); dyslipidemia (increased triglycelides 
≥150 mg/dL or reduced HDL cholesterol ˂40 mg/dL in men or ˂50 mg/dL in women); 
and hypertension (systolic ≥130 and/or diastolic ≥85 mmHg). Drug treatment for 
diabetes, dyslipidemia, or hypertension was an alternative indicator.  
This study was in accordance with the ethical guidelines for epidemiological 
research in Japan and was approved by the Ethics Committee of the Kyoto University 
Graduate School and Faculty of Medicine (approval code: E2029). 
 
Data collection  
History of alcohol intake was collected using an interview-sheet, and the data 
were confirmed by the participants’ families, doctors, and nurses. The indocyanine 
green retention rate at 15 min (ICG R15) was measured as a marker of preoperative 
liver function. Serum alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin 
(DCP) levels were measured before surgical treatment. Surgical complications were 
classified according to the Clavien-Dindo classification.19,20 In addition to pathological 
tumor characteristics, the pathological findings of non-cancerous liver tissue were 
evaluated. Presence of steatosis was defined according to the amount of surface area 
involved by fatty infiltration: none, <5%, 5-33%, and ˃33%. Even in cases with 
minimum steatosis (steatosis area ˂5%), patients were diagnosed as positive for 
steatosis. NBNC HCC patients with steatosis were further assessed according to their 
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NAFLD activity score (NAS)21. Liver fibrosis progression was recorded using the 
Metavir score22; F4 was defined as pathological cirrhosis. 
 
Statistical analysis 
Categorical variables were presented as numbers and percentages. Continuous 
variables were presented as mean ± standard deviation. Differences in categorical 
variables were analyzed using the chi-squared or Fisher’s exact test; continuous 
variables were compared using Mann-Whitney’s U test. Median survival and 95% 
confidence intervals (95% CIs) were determined using the Kaplan-Meier method; 
groups were compared using the log-rank test. Variables that were associated with 
survival at p<0.10 in univariate survival analysis were included in a multivariate Cox 
regression analysis, and hazard ratios (HRs) and 95% CIs were calculated. In all 
analyses, p<0.05 was considered statistically significant. JMP 10 software (SAS 
institute Inc. Cary, NC) was used in all statistical analyses. 
 
RESULTS 
Etiology of NBNC HCC  
The proportion of NBNC HCC patients who underwent surgical resection has 
recently increased (Figure 1). The etiology of NBNC HCC was multifactorial and 
complex, and we conventionally categorized patients according to the alcohol intake 
level and presence of pathological steatosis (Figure 2). ALD (n=43, 29.7%) was a major 
cause of disease, followed by NAFLD (n=19, 13.1%) and FLD (n=13, 9.0%), which 
were commonly characterized by steatosis without alcohol intake and steatosis with 
moderate alcohol intake, respectively. Despite the complexity of the etiological criteria, 
>40% of cases of NBNC HCC were categorized as cryptogenic HCC (n=64, 44.1%). In 
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such conventional cryptogenic cases, we tentatively established the criteria of Non-
Steatotic Met HCC: absence of heavy alcohol intake; absence of steatosis; and presence 
of metabolic syndrome-associated risk factors, including obesity, diabetes mellitus, 
dyslipidemia, or hypertension (Figure 2). Non-Steatotic Met HCC patients (n=43) 
accounted for 29.7% of all NBNC HCC cases and represented more than half of all 
cases originally categorized as cryptogenic HCC. Among the 6 patients with other 
known etiologies (4.1%), 4 had autoimmune hepatitis; 1, primary biliary cirrhosis; and 1, 
Budd-Chiari syndrome. 
 
Clinicopathologic characteristics of NBNC HCC  
The clinicopathologic characteristics of the NBNC HCC and BC HCC groups 
were examined (Table 1). Age, BMI, and the prevalence of diabetes mellitus and 
hypertension were significantly higher among NBNC HCC patients than among BC 
HCC patients. The NBNC HCC group had a greater proportion of patients with low 
alcohol intake (ethanol intake ≤20 g/day) and more patients who were heavy drinkers 
(ethanol intake >70 g/day), reflecting the etiological criteria of ALD and NAFLD. The 
hepatic functional reserve based on the Child-Pugh classification and ICG R15 and 
other liver damage indicators (e.g., transaminase and albumin levels, prothrombin 
activity, and platelet count), were better in the NBNC HCC group. Larger tumor size 
and higher serum DCP levels were preoperative tumor characteristics of the NBNC 
HCC group, whereas serum AFP levels were lower among these patients. The number 
of tumors, presence of microvascular invasion, and TNM stage were not significantly 
different between the 2 groups. Moreover, NBNC HCC patients were less likely to have 
fibrosis and more likely to display steatosis than BC HCC patients. The NBNC HCC 
group had more patients who underwent major hepatectomy; thereby, the surgical time 
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was longer in this group. Surgical blood loss and the rate of operative complications did 
not differ significantly between the groups.  
Furthermore, we examined the characteristics of each subdivision of NBNC 
HCC group (Supplemental Table 1). Cryptogenic HCC patients proved to have more 
advanced tumors, and they were characterized by higher DCP levels, and a higher rate 
of poorly differentiated tumor and microvascular invasion than Non-Steatotic Met HCC 
patients.  
We additionally examined the NAS of NAFLD-associated HCC patients 
(Supplemental Figure 1) as NAFLD ranges from simple steatosis to NASH. The 
diagnosis of NAFLD was made according to NAS ≥3, including possible NASH cases. 
The characteristics of these patients were assessed (Supplemental Table 2). The high 
NAS group had more advanced tumors than the low NAS group, but liver function and 
the prevalence of cirrhosis did not differ significantly. BMI and the rate of obesity were 
significantly higher in the low NAS group. 
 
Survival analysis of patients with NBNC HCC and BC HCC 
The median overall survival times of the NBNC HCC (n=145) and BC HCC 
groups (n=373) were 78.5 (95% CI, 59.9–85.5) and 72.4 months (95% CI, 58.4–81.4), 
respectively (p=0.436). The median disease-free survival times among patients in the 
NBNC HCC (n=126) and BC HCC groups (n=304) who underwent curative resection 
were 24.5 (95% CI, 19.5–33.8) and 20.5 months (95% CI, 17.6–25.3), respectively 
(p=0.2953). Prognosis in the 2 groups did not differ significantly. Among the various 
etiologies, the overall and disease-free survival rates of NAFLD-associated HCC 
patients were better than those of ALD-associated HCC and BC HCC patients (see 
Supplemental Figures 2 and 3). On the other hand, the prognosis of Non-Steatotic Met 
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HCC and cryptogenic HCC was similarly as poor as that of ALD-associated HCC or BC 
HCC. 
Table 2 presents the results of univariate and multivariate analyses of the 
disease-free survival of NBNC HCC patients who underwent curative resection. 
Alcohol intake levels and the prevalence of obesity, diabetes, or dyslipidemia were not 
associated with disease-free survival. Although several studies reported that serum 
hepatitis B core (HBc) antibody positivity, also termed “occult hepatitis B virus 
infection,” is a risk factor for NBNC HCC,8,23,24 we did not identify significant 
involvement of HBc antibody positivity in the risk of NBNC HCC recurrence. 
Multivariate analysis revealed that the presence of microvascular invasion and steatosis 
area ˂5% of non-cancerous region were significantly associated with disease-free 
survival after curative resection (Table 2). However, liver cirrhosis did not significantly 
affect the recurrence risk among NBNC HCC patients. 
 
Impact of steatosis on disease-free survival 
Liver cirrhosis is a powerful risk factor for HCC development, and it was 
consistent with the disease-free survival of BC HCC patients in our study 
(Supplemental Figure 4). In NBNC HCC patients, liver cirrhosis did not affect the 
recurrence risk (Supplemental Figure 5). On the other hand, the absence of steatosis was 
associated with the disease-free survival of NBNC HCC patients (Supplemental Figure 
6), but not with that of BC HCC patients (Supplemental Figure 7). The relationship 
between steatosis area and disease-free survival is shown in Figure 3 and suggests that a 
lesser extent of steatosis led to a higher risk of HCC progression. 
To assess the possibility that the absence of steatosis might be a consequence of 
liver fibrosis progression, thus explaining the poor prognosis of NBNC HCC patients, 
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we analyzed the correlations between steatosis and liver fibrosis. Liver fibrosis was 
scored in NBNC HCC patients with steatosis area ≥5% (n=39) as: F0, 25.6%; F1, 
20.5%; F2, 18.0%; F3, 10.3%; and F4, 25.6%. Conversely, liver fibrosis in NBNC HCC 
patients with steatosis area <5% (n=95) was categorized as: F0, 20.7%; F1, 34.0%; F2, 
13.2%; F3, 12.3%; and F4, 19.8%. No correlations between the extent of steatosis and 
the progression of fibrosis were found. 
 
DISCUSSION 
Recently, the prevalence of NBNC HCC has rapidly increased.11,25 NAFLD and 
NASH, the major causes of NBNC HCC, are associated with metabolic syndrome risk 
factors.13,16,26-28 The epidemic rise in obesity and metabolic syndrome might explain the 
increase in the NBNC HCC prevalence in Japan and Western countries. Our study 
showed that the proportion of NBNC HCC patients who underwent surgical resection 
has also increased. The prevalence of obesity, diabetes mellitus, and hypertension was 
higher among NBNC HCC patients than among BC HCC patients, suggesting that 
obesity and metabolic syndrome are important risk factors for NBNC HCC. The tumor 
sizes of the NBNC HCC group were significantly larger than those of the BC HCC 
group. As their hepatic function was relatively preserved, NBNC HCC patients were 
frequently diagnosed incidentally or symptomatically without follow-up for their liver 
damage, possibly resulting in tumor progression at the time of detection. The higher 
serum DCP levels of NBNC HCC patients might be related with the larger tumor size of 
these patients, whereas the lower serum AFP levels implied less progression of liver 
damage.29-32 Major hepatectomy was frequently performed among NBNC HCC patients, 
owing to the large tumor size and good hepatic function reserve. Our survival analysis 
after surgical treatment revealed no significant difference in prognosis between the 2 
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groups, suggesting that the better hepatic functional reserve of NBNC HCC patients is 
offset by their more advanced tumors. 
Multivariate survival analysis revealed that microvascular invasion and smaller 
steatosis area in the parenchyma were associated with the disease-free survival of 
NBNC HCC patients. Interestingly, pathological steatosis had a stronger effect on the 
recurrence risk after curative resection than pathological liver fibrosis, which is the 
strongest predisposing factor for HCC development.1,3,4 Our study indicated that the 
absence of steatosis, but not its promotion, was involved in higher recurrence risk. 
Patients with NAFLD-associated HCC had a significantly lower recurrence risk than 
patients with ALD-associated HCC and BC HCC. However, the recurrence risks of 
Non-Steatotic Met HCC patients, who did not fulfill the pathological criteria for 
NAFLD but exhibited metabolic syndrome-associated risk factors, were not different 
from those of ALD-associated HCC and BC HCC patients. Absence of steatosis in the 
NBNC HCC background might indicate the presence of somewhat chronic liver damage 
not characterized by the promotion of liver fibrosis. 
This study has several potential limitations. First, self-reports on alcohol intake 
might be inaccurate. However, we attempted to overcome such a limitation by using a 
questionnaire form and verifying patient reports with doctors, nurses, and families. 
Second, the presence of steatosis was based on focal observation of the non-cancerous 
region of the resected liver tissue and it did not necessarily represent the characteristics 
of the entire underlying parenchymal changes. Third, the prevalence of obesity and 
metabolic syndrome in the Japanese population differs from that of Western countries, 
and so we had to partly modify the international diagnostic criteria of obesity and 
metabolic syndrome. 
In conclusion, chronic alcohol consumption, metabolic syndrome, and their 
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common pathological consequence (i.e., steatosis) are risk factors for NBNC HCC 
development. Absence of steatosis had a stronger impact on disease-free survival than 
liver fibrosis in NBNC HCC patients. In postoperative surveillance and lifestyle 
education, we should devote more attention to such patients with NBNC HCC and those 
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FIGURE LEGENDS 
Figure 1 The time trend of the proportion of HCC patients who underwent hepatic 
resection.  
Figure 2 Etiological criteria of NBNC HCC. The vertical axis indicates the alcohol 
intake amount; the horizontal axis indicates the presence of steatosis. Each etiological 
category is enclosed in a rectangle. Non-steatotic and metabolic syndrome-associated 
HCC (Non-Steatotic Met HCC) is shown as a gray-fill pattern. Cases of other known 
etiology are not shown. 
Figure 3 Comparison of disease-free survival rates according to the steatosis area of 
non-cancerous region in NBNC HCC patients who underwent curative resection. 
Median survival time (MST), 95% CI, and disease-free survival rate at 5 years (5-year 
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TABLES 
Table 1 Clinicopathologic characteristics of NBNC HCC and BC HCC patients  
  
NBNC HCC (n = 145) BC HCC (n = 373) p value 
Clinical backgrounds 
     
Gender Male 120 (82.8%) 283 (75.9%) 0.0844 
 




69 ±9.3 64 ±10.6 <0.0001 
BMI, kg/ m2 
 
23.7 ±3.8 23.0 ±3.2 0.0465 
Obesity, + 
 
42 (28.0%) 86 (23.1%) 0.166 
Diabetes, + 
 
62 (42.7%) 78 (20.9%) <0.0001 
Dyslipidemia, + 20 (13.8%) 31 (8.3%) 0.068 
Hypertension, + 68 (46.9%) 138 (37.0%) 0.0397 
Ethanol intake >70 g/day 43 (29.9%) 31 (8.5%) <0.0001 
Ethanol intake <20 g/day 74 (51.4%) 265 (72.8%) <0.0001 
Liver functions 
    
ICG R15, % 
 
15.3 ±8.5 18 ±11.6 0.0200 
Child-Pugh classification A 138 (95.2%) 332 (89.0%) 0.0212 
 




43.5 ±27.7 59.6 ±39.7 <0.0001 
ALT, IU/l 
 
41.1 ±34.9 56.5 ±44.9 <0.0001 
  21 
Platelet count, x103/μl 
 
175.6 ±88.5 142.3 ±69.5 <0.0001 
 Prothrombin activity, % 
 
86.1 ±14.3 83.7 ±12.7 0.0469 
Total bilirubin, mg/dl 
 
0.84 ±0.50 0.86 ±0.40 0.0808 
Albumin, mg/dl 
 
4.00 ±0.37 3.88 ±0.49 0.0069 
Tumor characteristics 
     
AFP, ng/ml 
 
5927.3 ±25000 12133.0 ±150877 0.0011 
DCP, mAU/ml 12217.5 ±33905.5 7011.8 ±25878.6 0.0016 
Tumor size, cm 6.6 ±4.3 4.8 ±3.5 <0.0001 
Number of tumors Solitary 91 (62.8%) 239 (64.1%) 0.7799 
 
Multiple 54 (37.2%) 134 (35.9%) 
 
Tumor differentiation Well 10 (7.0%) 57 (15.8%) 0.0071 
 
Moderate 103 (72.5%) 215 (59.9%) 
 
 
Poor 29 (20.4%) 87 (24.2%) 
 
Microvascular invasion, + 57 (39.3%) 136 (36.5%) 0.5479 
Lymph node involvement, + 1 (0.7%) 4 (1.1%) 0.6791 
TNM Stage I, II 100 (69.0%) 286 (76.7%) 0.0742 
 
III, IV 45 (31.0%) 87 (23.3%) 
 
Underlying parenchymal changes 
     
Steatosis, + 50 (34.5%) 56 (15.1%) <0.0001 
Cirrhosis, + 
 
31 (21.4%) 156 (41.8%) <0.0001 
  22 
Surgical factors 
     
Surgical procedure ≥Lobectomy 66 (45.5%) 139 (37.3%) 0.0351 
 
Segmentectomy 32 (22.1%) 67 (17.9%) 
 
 
≤Subsegmentectomy 47 (32.4%) 167 (44.8%) 
 
Surgical time, min 384.7 ±126.1 362.5 ±140.4 0.0190 
Surgical blood loss, ml 1913.2 ±2883.5 1682.7 ±2874.8 0.4435 
Surgical complication Grade ≥III 27 (18.6%) 83 (22.2%) 0.3595 
 
No, Grade ≤II 118 (81.4%) 290 (77.8%) 
 
Curativity Curative resection 126 (86.9%) 304 (81.5%) 0.1337 
 
Not curative resection 19 (13.1%) 69 (18.5%) 
 
Data represent the mean ± standard deviation or the number of patients. 
NBNC HCC: non-B non-C hepatocellular carcinoma 
BC HCC: hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma 
BMI: body mass index 
ICG R15: indocyanine green retention rate at 15 minutes 
AST: asparatate aminotransferase 
ALT: alanine aminotransferase 
AFP: alpha-fetoprotein 
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Table 2 Disease-free survival analysis in NBNC HCC patients 
 




95% CI p value Hazard ratio 95% CI p value 
Gender Male 26.5 (22.3-45.1) 0.0331 0.84 (0.47-1.60) 0.5978 
 




Age ≥65 yr 23.7 (19.5-31.4) 0.8122 
   
 
<65 yr 27.5 (9.7-71.7) 
    
Obesity + 39.6 (18.4- .) 0.1837 
   
 
- 23.0 (15.3-28.6) 
    
Ethanol intake ≥70 g/day 24.1 (11.7-33.8) 0.2035 
   
 
˂70 g/day 26.5 (18.4-71.7) 
    
Ethanol intake ≥20 g/day 25.2 (13.1-33.8) 0.1504 
   
 
<20 g/day 27.5 (16.3-102.7) 
    
Diabetes + 28.6 (14.8-71.7) 0.25 
   
 
- 21.9 (16.3-29.1) 
    
Dyslipidemia + 45.8 (12.4- . ) 0.1812 
   
 
- 22.5 (18.0-28.6) 
    
Hypertension + 20.9 (12.7-25.5) 0.0361 1.38 (0.82-2.34) 0.2228 
 




HBcAb + 27.5 (13.4-64.7) 0.3021 
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- 20.3 (9.4-34.2) 
    
ICG R15 ≥15% 27.5 (19.4-39.6) 0.3451 
   
 
˂15% 22.3 (15.3-71.7) 
    
Child-Pugh classification  A 24.5 (19.4-34.2) 0.9974 
   
 
B 27.9 (9.7- . ) 
    
AFP ≥20 ng/ml 16.1 (9.0-27.5) 0.0648 1.25 (0.74-2.09) 0.3926 
 




DCP ≥40 mAU/ml 20.9 (14.8-26.5) 0.0069 1.99 (0.99-4.46) 0.0539 
 




Tumor size ≥5 cm 19.7 (12.4-33.8) 0.2645 
   
 
˂5 cm 27.5 (22.3-58.2) 
    
Number of tumors Multiple 16.3 (9.7-25.5) 0.0036 1.47 (0.83-2.55) 0.1864 
 




Microvascular invasion + 9.7 (8.0-13.4) <0.0001 2.30 (1.33-3.96) 0.0032 
 




Tumor differentiation Well to moderate 25.5 (19.7-45.1) 0.149 
   
 
Poor 13.9 (5.2-41.6) 
    
Steatosis <5% 18.4 (16.3-28.6) 0.0036 2.13 (1.21-3.93) 0.0077 
 




Cirrhosis + 24.5 (13.0-71.7) 0.9701 
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- 24.1 (16.3-39.6) 
    
TNM Stage I, II 31.4 (22.5-64.7) <0.0001 0.72 (0.39-1.35) 0.3119 
 




Surgical procedure ≥Lobectomy 15.3 (9.5-25.2) 0.0256 0.71 (0.40-1.26) 0.2454 
 




Surgical time ≥360 min 25.5 (15.3-45.1) 0.7861 
   
 
˂360 min 22.3 (16.1-41.6) 
    
Surgical blood loss ≥1000 ml 24.5 (15.3-34.2) 0.6795 
   
 
˂1000 ml 24.1 (18.4-45.8) 
    
Surgical complication Grade ≥III 26.5 (6.7-34.2) 0.7051 
   
 
No, Grade ≤II 24.1 (18.4-41.6) 
    
Curative resection cases of NBNC HCC (n = 126) were analyzed. 
Blanks in the upper limit of 95% CI represent unreached. 
NBNC HCC: non-B non-C hepatocellular carcinoma 
MST: median survival time 
95% CI: 95% confidence intervals 
HBcAb: hepatitis B core antibody 
ICG R15: indocyanine green retention rate at 15 minutes 
AFP: alpha-fetoprotein 
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48 72 96 120 
Time after surgery (months) 
N 
MST 95%CI 5-year (months) DFS rate 
7 ( 6.3 - ) 71.4% ]· ]t 28 41.6 (23.0 - ) 49.2% 
91 18.4 (3.8 
-
) 25.7% 
*p = 0.0156 
tp = 0.0463 
LEGENDS OF SUPPLEMENTAL FIGURES 
Supplemental Figure 1 The components of NAFLD activity score of NAFLD-associated HCC 
patients.  
Supplemental Figure 2 Comparisons of overall survival rates among the etiologies. The 
survival line of other known etiology cases was omitted. Median survival time (MST), 95% CI, 
and overall survival rate at 5 years (5-year OS rate), are shown below the graph. Blanks in MST 
and the upper limit of 95% CI represent unreached. All groups were compared using the log-rank 
test; the combinations of groups with p<0.10 were represented. 
Supplemental Figure 3 Comparisons of disease-free survival rates among the etiologies in 
patients who underwent curative resection. The survival line of other known etiology cases was 
omitted. Median survival time (MST), 95% CI, and disease-free survival rate at 5 years (5-year 
DFS rate) are shown below the graph. Blanks in MST and the upper limit of 95% CI represent 
unreached. All groups were compared using the log-rank test; the combinations of groups with 
p<0.10 were represented. 
Supplemental Figure 4 Comparison of disease-free survival rates according to the presence of 
liver cirrhosis in BC HCC patients who underwent curative resection. Median survival time 
(MST), 95% CI, and disease-free survival rate at 5 years (5-year DFS rate) are shown below the 
graph. 
Supplemental Figure 5 Comparison of disease-free survival rates according to the presence of 
liver cirrhosis in NBNC HCC patients who underwent curative resection. Median survival time 
(MST), 95% CI, and disease-free survival rate at 5 years (5-year DFS rate) are shown below the 
graph. 
Supplemental Figure 6 Comparison of disease-free survival rates according to the presence of 
steatosis in NBNC HCC patients who underwent curative resection. Median survival time (MST), 
95% CI, and disease-free survival rate at 5 years (5-year DFS rate) are shown below the graph. 
Supplemental Figure 7 Comparison of disease-free survival rates according to the presence of 
steatosis in BC HCC patients who underwent curative resection. Median survival time (MST), 
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Supplemental Table 1 Clinicopathologic characteristics of each subdivision of the NBNC HCC group 
ALD (n = 43) NAFLD (n = 19) FLD (n = 13) Non-Steatotic Met (n = 43) Cryptogenic (n = 21) 
Clinical backgrounds 
Gender Male 43 (100.0%) †¶§ 15 (79.0%) *‡ 13 (100.0%) †¶§ 33 (76.7%) *‡ 13 (61.9%) *‡ 
Female 0 (0.0%) 4 (21.0%) 0 (0.0%) 10 (23.3%) 8 (38.1%) 
Age, yr 68 ±7.3 ¶ 69 ±8.3 § 69 ±8.9 72 ±8.9 *§ 62 ±11.8 †¶ 
BMI, kg/ m2 23.3 ±3.1 †‡§ 25.9  ±3.4 *¶§ 26.9  ±4.9 *¶§ 23.4  ±3.3 †‡§ 20.7  ±2.7 *†‡¶ 
Obesity, + 10 (23.3%) †‡§ 10 (52.6%) *§ 7 (53.9%) *§ 14 (32.6%) § 0 (0.0%) *†‡¶ 
Diabetes, + 19 (44.2%) § 12 (63.2%) § 5 (38.5%) § 23 (53.5%) § 0 (0.0%) *†‡¶ 
Dyslipidemia, + 9 (20.9%) § 3 (15.8%) § 3 (23.1%) § 4 (9.3%) 0 (0.0%) *†‡ 
Hypertension, + 20 (46.5%) ¶§ 9 (47.4%) § 7 (53.9%) § 29 (67.4%) *§ 0 (0.0%) *†‡¶ 
Ethanol intake > 70g/day 43 (100.0%) †‡¶§ 0 (0.0%) * 0 (0.0%) * 0 (0.0%) * 0 (0.0%) * 
Ethanol intake < 20g/day 0 (0.0%) †¶§ 19 (100.0%) *‡¶§ 0 (0.0%) †¶§ 36 (83.7%) *†‡ 14 (70.0%) *†‡ 
Liver functions 
ICG R15 18.9 ±10.8 § 13.2 ±7.1 14.4 ±6.6 14.4 ±6.8 11.7 ±6.2 * 
Child-Pugh classification A 40 (93.0%) 18 (94.7%) 12 (92.3%) 41 (95.4%) 21 (100.0%) 
B 3 (7.0%) 1 (5.3%) 1 (7.7%) 2 (4.6%) 0 (0.0%) 
Tumor characteristics 
AFP, ng/ml 4984.4  ±21425 § 420.8  ±1337 § 878.1  ±2772 8516.9  ±29340 11400.1  ±40264 *† 
DCP, mAU/ml 14544.0  ±37218 6581.9  ±11083 906.0  ±1277 § 7492.4  ±18006 § 30861.0  ±62991 ‡¶ 
Tumor size, cm 5.5 ±3.9 ¶§ 5.2 ±2.3 ¶§ 4.5 ±2.4 ¶§ 7.9 ±4.3 *†‡ 9.7 ±5.4 *†‡ 
Number of tumors Solitary 21 (48.8%) § 13 (68.4%) 7 (53.9%) 29 (67.4%) 16 (76.2%) * 
Multiple 22 (51.2%) 6 (31.6%) 6 (46.1%) 14 (32.6%) 5 (23.8%) 
Tumor differentiation Well 4 (9.7%) § 0 (0.0%) 1 (7.7%) 5 (11.9%) § 0 (0.0%) *¶ 
Moderate 30 (73.2%) 16 (84.2%) 10 (76.9%) 30 (71.4%) 12 (57.1%) 
Poor 7 (17.1%) 3 (15.8%) 2 (15.4%) 7 (16.7%) 9 (42.9%) 
Microvascular invasion, + 18 (41.9%) 7 (36.8%) 4 (30.8%) 14 (32.6%) § 13 (61.9%) ¶ 
TNM Stage I, II 32 (74.4%) 13 (68.4%) 11 (84.6%) § 27 (62.8%) 11 (52.4%) ‡ 
III, IV 11 (25.6%) 6 (31.6%) 2 (15.4%) 16 (37.2%) 10 (47.6%) 
Underlying parenchymal changes 
Steatosis, + 15 (34.9%) †‡¶§ 19 (100.0%) *¶§ 13 (100.0%) *¶§ 0 (0.0%) *†‡ 0 (0.0%) *†‡ 
<5% 4 (9.3%) 2 (10.5%) 4 (30.8%) 0 (0.0%) 0 (0.0%) 
5-33% 8 (18.6%) 13 (68.4%) 9 (69.2%) 0 (0.0%) 0 (0.0%) 
>33% 3 (7.0%) 4 (21.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Cirrhosis, + 13 (30.2%) 2 (10.5%) 3 (23.1%) 7 (16.3%) 4 (19.1%) 
Data represent the mean ± standard deviation or the number of patients. 
NBNC HCC: non-B non-C hepatocellular carcinoma 
ALD: alcoholic liver disease 
NAFLD: nonalcoholic fatty liver disease 
FLD: fatty liver disease 
Non-Steatotic Met: non-steatotic and metabolic syndrome-associated 
BMI: body mass index 
ICG R15: indocyanine green retention rate at 15 minutes 
AFP: alpha-fetoprotein 
DCP: des-gamma-carboxy prothrombin 
*: p ˂0.05 vs. ALD, †: p <0.05 vs. NAFLD, ‡: p <0.05 vs. FLD, ¶: p <0.05 vs. Non-Steatotic Met, §: p <0.05 vs. Cryptogenic 
Supplemental Table 2 Clinicopathologic characteristics of NAFLD associated-HCC patients according to the NAS category 
NAS ˂3 (n =10) NAS ≥3 (n = 9) p value 
Clinical backgrounds 
Gender Male 9 (90.0%) 6 (66.7%) 0.2062 
Female 1 (10.0%) 3 (33.3%) 
Age, yr 67.5 ±10.1 70.1 ±6.0 0.7741 
BMI, kg/ m2 27.8 ±3.5 23.9 ±1.7 0.0062 
Obesity, + 8 (80.0%) 2 (22.2%) 0.0094 
Diabetes, + 6 (60.0%) 6 (66.7%) 0.7633 
Dyslipidemia, + 1 (10.0%) 2 (22.2%) 0.4633 
Hypertension, + 6 (60.0%) 3 (33.3%) 0.2419 
Liver functions 
ICG R15 14.6 ±8.6 11.7 ±5.1 0.5937 
Child-Pugh classification A 9 (90.0%) 1 (10.0%) 0.0212 
B 1 (100.0%) 0 (0.0%) 
Tumor characteristics 
AFP, ng/ml 72.0 ±169.3 808.4 ±1915.4 0.6830 
DCP, mAU/ml 2084.3 ±5055.6 11579.3 ±13936.6 0.0792 
Tumor size, cm 4.8 ±2.6 5.7 ±2.0 0.4375 
Number of tumors Solitary 8 (80.0%) 5 (55.6%) 0.3498 
Multiple 2 (20.0%) 4 (44.4%) 
Tumor differentiation Well 0 (0.0%) 0 (0.0%) 0.0237 
Moderate 10 (100.0%) 6 (66.7%) 
Poor 0 (0.0%) 3 (33.3%) 
Microvascular invasion, + 1 (10.0%) 6 (66.7%) 0.0079 
TNM Stage I, II 9 (90.0%) 4 (44.4%) 0.0279 
III, IV 1 (10.0%) 5 (55.6%) 
Underlying parenchymal changes 
Cirrhosis, + 1 (10.0%) 1 (11.1%) 0.9372 
Fibrosis stage F0 2 (20.0%) 1 (11.1%) 
F1 2 (20.0%) 3 (33.3%) 
F2 4 (40.0%) 2 (22.2%) 
F3 1 (10.0%) 2 (22.2%) 
F4 1 (10.0%) 1 (11.1%) 
Data represent the mean ± standard deviation or the number of patients. 
NAFLD: nonalcoholic fatty liver disease 
HCC: hepatocellular carcinoma 
NAS: NAFLD activity score 
BMI: body mass index 
ICG R15: indocyanine green retention rate at 15 minutes 
AFP: alpha-fetoprotein 
DCP: des-gamma-carboxy prothrombin 
